Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Frexalimab - ImmuNext/Sanofi

Drug Profile

Frexalimab - ImmuNext/Sanofi

Alternative Names: INX 021; SAR-441344

Latest Information Update: 19 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmuNext
  • Developer Sanofi
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action CD40 ligand inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Multiple sclerosis
  • Phase II Sjogren's syndrome; Systemic lupus erythematosus; Type 1 diabetes mellitus

Most Recent Events

  • 19 Feb 2024 Sanofi announces intention to submit an application to the regulatory body for Multiple sclerosis (SC, IV), in 2026 or beyond (Sanofi pipeline, February 2024)
  • 15 Feb 2024 Efficacy data from a phase II trial in Multiple sclerosis released by Sanofi
  • 01 Feb 2024 Sanofi completes a phase II Sjogren's-syndrome trial in Sjogren's syndrome (In adults, In the elderly) in Canada, Argentina, Belgium, Chile, France, Germany, Hungary, Mexico, South Korea, Spain, Taiwan and the US (NCT04572841) (EudraCT2020-000511-77)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top